JP2019515027A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515027A5
JP2019515027A5 JP2019505138A JP2019505138A JP2019515027A5 JP 2019515027 A5 JP2019515027 A5 JP 2019515027A5 JP 2019505138 A JP2019505138 A JP 2019505138A JP 2019505138 A JP2019505138 A JP 2019505138A JP 2019515027 A5 JP2019515027 A5 JP 2019515027A5
Authority
JP
Japan
Prior art keywords
binding fragment
antigen
hvegf
hvegf antigen
glycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019505138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515027A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027650 external-priority patent/WO2017181021A1/en
Publication of JP2019515027A publication Critical patent/JP2019515027A/ja
Publication of JP2019515027A5 publication Critical patent/JP2019515027A5/ja
Priority to JP2022108815A priority Critical patent/JP2022153418A/ja
Priority to JP2024152809A priority patent/JP2025000642A/ja
Pending legal-status Critical Current

Links

JP2019505138A 2016-04-15 2017-04-14 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療 Pending JP2019515027A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022108815A JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2024152809A JP2025000642A (ja) 2016-04-15 2024-09-05 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662323285P 2016-04-15 2016-04-15
US62/323,285 2016-04-15
US201762442802P 2017-01-05 2017-01-05
US62/442,802 2017-01-05
US201762450438P 2017-01-25 2017-01-25
US62/450,438 2017-01-25
US201762460428P 2017-02-17 2017-02-17
US62/460,428 2017-02-17
PCT/US2017/027650 WO2017181021A1 (en) 2016-04-15 2017-04-14 Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022108815A Division JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Publications (2)

Publication Number Publication Date
JP2019515027A JP2019515027A (ja) 2019-06-06
JP2019515027A5 true JP2019515027A5 (OSRAM) 2020-05-28

Family

ID=60041925

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019505138A Pending JP2019515027A (ja) 2016-04-15 2017-04-14 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2022108815A Pending JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2024152809A Pending JP2025000642A (ja) 2016-04-15 2024-09-05 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022108815A Pending JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2024152809A Pending JP2025000642A (ja) 2016-04-15 2024-09-05 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Country Status (9)

Country Link
US (3) US20190127455A1 (OSRAM)
EP (1) EP3442577A4 (OSRAM)
JP (3) JP2019515027A (OSRAM)
KR (2) KR20240005973A (OSRAM)
AU (2) AU2017250797A1 (OSRAM)
CA (1) CA3019665A1 (OSRAM)
IL (1) IL262277A (OSRAM)
SG (2) SG11201808440YA (OSRAM)
WO (1) WO2017181021A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
IL262207B1 (en) 2016-04-15 2025-09-01 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
WO2019067540A1 (en) * 2017-09-27 2019-04-04 Regenxbio Inc. TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB
MY207644A (en) 2017-12-19 2025-03-07 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
US20210093734A1 (en) * 2018-02-20 2021-04-01 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-realted macular degeneration
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
IL313246B2 (en) * 2018-06-28 2025-10-01 Univ North Carolina Chapel Hill Optimal cln5 expression genes and cassettes and their use
CN118497276A (zh) * 2018-11-07 2024-08-16 阿库斯股份有限公司 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
CN113966236A (zh) 2019-04-03 2022-01-21 再生生物股份有限公司 眼睛病状的基因疗法
SG11202111414RA (en) * 2019-04-24 2021-11-29 Regenxbio Inc Fully-human post-translationally modified antibody therapeutics
KR20220049568A (ko) * 2019-08-22 2022-04-21 더 리전츠 오브 더 유니버시티 오브 캘리포니아 엔젤만 증후군의 치료를 위한 ube3a
AU2020336314A1 (en) * 2019-08-26 2022-04-07 Regenxbio Inc. Treatment of diabetic retinopathy with fully-human post-translationally modified anti-VEGF Fab
JP2022552262A (ja) 2019-10-07 2022-12-15 リジェネックスバイオ インコーポレイテッド アデノ随伴ウイルスベクター医薬組成物および方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CA3194861A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Formulations for suprachoroidal administration such as gel formulations
US20240024508A1 (en) 2020-10-07 2024-01-25 Regenxbio Inc. Formulations for suprachoroidal administration such as high viscosity formulations
EP4225381A1 (en) 2020-10-07 2023-08-16 RegenxBio Inc. Formulations for suprachoroidal administration such as formulations with aggregate formation
IL301643A (en) 2020-10-07 2023-05-01 Regenxbio Inc Gene therapy for ocular manifestations of CLN2 disease
AR123948A1 (es) * 2020-10-28 2023-01-25 Regenxbio Inc ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
WO2022119839A1 (en) 2020-12-01 2022-06-09 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
KR20230121096A (ko) * 2020-12-18 2023-08-17 에이씨 이뮨 에스에이 항체 전달
CA3209779A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
JP2024513205A (ja) * 2021-03-31 2024-03-22 ウーシー バイオロジクス アイルランド リミテッド 二重特異性抗pd-l1/vegf抗体およびその使用
TW202345913A (zh) 2022-04-06 2023-12-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如凝膠調配物
EP4504149A1 (en) 2022-04-06 2025-02-12 RegenxBio Inc. Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoidal administration
TW202404651A (zh) 2022-04-06 2024-02-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如形成聚集體之調配物
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1573601A (en) * 1999-10-21 2001-04-30 Monsanto Company Post-translational modification of recombinant proteins produced in plants
AU2001280841A1 (en) * 2000-07-26 2002-02-05 Licentia Ltd. Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
US9079953B2 (en) * 2009-06-17 2015-07-14 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
TWI702955B (zh) * 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
PT3142750T (pt) * 2014-05-13 2020-09-22 Univ Pennsylvania Composições que compreendem aav expressando construções de anticorpos duplos e suas utilizações

Similar Documents

Publication Publication Date Title
JP2019515027A5 (OSRAM)
JP7523491B2 (ja) Pd-1、tim-3、およびlag-3を標的とする併用治療
JP2016504416A5 (OSRAM)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2016188209A5 (OSRAM)
RU2015121755A (ru) Антагонисты ил-6 и их применение
RU2018125515A (ru) Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2018506277A5 (OSRAM)
JP2018510617A5 (OSRAM)
JP2018517431A5 (OSRAM)
JP2020514277A5 (OSRAM)
JP2018527919A5 (OSRAM)
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
JP2017501711A5 (OSRAM)
JP2017535257A5 (OSRAM)
JP2016094424A5 (OSRAM)
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2010526028A5 (OSRAM)
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
JP2014509510A5 (OSRAM)
IL276383B2 (en) Treatment of ophthalmologic diseases
JP2019530427A5 (OSRAM)
JP2019505527A5 (OSRAM)
JP2019532617A5 (OSRAM)
JP2018512402A5 (OSRAM)